Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Evaluating SLN12140 in Complement Inhibitor-Naïve Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria

NCT07387302 is registered in ClinicalTrials.gov with Linno Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07387302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07387302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Evaluating SLN12140 in Complement Inhibitor-Naïve Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria
Lead sponsor
Linno Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 10, 2026
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria (pnh)